Nephrogenic systemic fibrosis and contrast medium-induced nephropathy: A choice between the devil and the deep blue sea for patients with reduced renal function?

Acta Radiologica

Volumn 50, Issue 9, 2009, Pages 965-967

  Ramskov, Lind K ^a   Thomsen, H S ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST AGENT; CONTRAST MEDIUM; DEEP BLUE; LOWER EXTREMITY; NEPHROGENIC SYSTEMIC FIBROSIS; NEPHROPATHY; RENAL FUNCTIONS;

DIALYSIS; GADOLINIUM; SUPERCOMPUTERS;

CONTRAST MEDIA;

CONTRAST MEDIUM; GADOLINIUM;

CHEMICALLY INDUCED DISORDER; COMPUTER ASSISTED TOMOGRAPHY; DRUG CONTRAINDICATION; EDITORIAL; HUMAN; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIATION DOSE; RENAL REPLACEMENT THERAPY; RISK FACTOR;

CONTRAST MEDIA; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; NEPHROGENIC FIBROSING DERMOPATHY; RADIATION DOSAGE; RENAL DIALYSIS; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 70449461363     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.3109/02841850903209218     Document Type: Review

References (21)

1. Grobner T. Gadolinium a specific trigger for the development of nephrogenic .brosing dermopathy and nephrogenic systemic .brosis? Nephrol Dial Transplant 2006;/21:/1104-8.
2. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, et al. Nephrogenic systemic .brosis: suspected etiological role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;/17:/2359-62.
3. Dawson P, Punwani S. Nephrogenic systemic .brosis: non gadolinium options for the imaging of CKD/ESRD patients. Semin Dial 2008;/21:/160-5.
4. Smith H, editor. Annals of the ICRP:1990 recommendations of the International Commission on Radiologcal Protection. London:Pergamon Press; 1990. p. 176.
5. Academic members of the Contrast Media Safety Committee. ESUR guidelines on contrast media. In: Thomsen HS, Webb JAW, editors. Contrast media. Safety issues and ESUR guidelines. Heidelberg: Springer; 2009. p. 229-42.
6. Bartlett MJ, Bynevelt M. Acute contrast reaction management by radiologists:a local audit study. Austr Radiol 2003;/47:/363-7.
7. Lightfoot CB, Abraham RJ, Mammen T, Abdolell M, Kapur S, Abraham RJ. Survey of radiologists' knowledge regarding management of severe contrast materialinduced allergic reactions. Radiology 2009;/251:/691-6.
8. Morcos SK. Dialysis and contrast media. In:Thomsen HS, Webb JAW, editors. Contrast media. Safety issues and ESUR guidelines. Heidelberg:Springer; 2009. p. 81-5.
9. Thomsen HS, Morcos SK, Barrett BJ. Contrast-induced nephropathy:the wheel has turned 360 degrees. Acta Radiol 2008;/49:/646-57.
10. Thomsen HS. Contrast medium induced nephropathy. In:Thomsen HS, Webb JAW, editors. Contrast media. Safety issues and ESUR guidelines. Heidelberg: Springer; 2009. p. 63-80.
11. Solomon RJ, Mehran R, Natarjan MK, Doucet S, Katholi RE, Staniloae CS, et al. Contrast-induced nephropathy and long-term advice events:cause and effect? Clin J Am Soc Nephrol 2009;/4:/1162-9.
12. Sadeghi HM, Stone GW, Grines CL, Mehran R, Dixon SR, Lansky AJ, et al. Impact of renal insuf.ciency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 2003;/108:/2769-75.
13. Thomsen HS, Marckmann P, Logager VB. Update on nephrogenic systemic .brosis. Magn Reson Imaging Clin N Am 2008;/16:/551-60.
14. Stenver DI. Pharmacovigilance:what to do if you see an adverse reaction and the consequences. Eur J Radiol 2008;/66:/184-8.
15. Thomsen HS. Delayed reactions:nephrogenic systemic .brosis. In:Thomsen HS, Webb JAW, editors. Contrast media. Safety issues and ESUR guidelines. Heidelberg: Springer; 2009. p. 187-96.
16. Thomsen HS, Marckmann P. Extracellular Gd-CA. Differences in prevalences of NSF. Eur J Radiol 2008;66:180-3.
17. Marckmann P, Skov L, Rossen K, Thomsen HS. Clinical manifestations of gadodiamide-related nephrogenic systemic .brosis. Clin Nephrol 2008;/69:/161-8.
18. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic .brosis in chronic renal failure patients exposed to gadodiamide, a gadolinium( Gd)-containing magnetic resonance contrast agent. Invest Radiol 2008;/43:/65-75.
19. Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic .brosis. Predictor of early mortality and association with gadolinium exposure. Arthritis Rheumatol 2007;/56:/3433-41.
20. Wahba IM, Simpson EL, White K. Gadolinium is not the only trigger for nephrogenic systemic .brosis:insights from two cases and review of the recent literature. Am J Transplant 2007;/7:/2425-32.
21. Newhouse JH, Kho D, Rao QA. Frequency of serum creatinine changes in the absence of iodinated contrast material:implications for studies of contrast nephrotoxicity. Am J Roentgenol 2008;/191:/376-82.